CClinicalTrials.gg
Status unknownNCT04144296Updated Sep 21, 2021

Mathematical Arterialisation of Capillary Blood for Blood Gas Analysis in Critical Ill Patients

An interventional study of Study procedure in Lung Diseases, sponsored by RWTH Aachen University. Status unknown at 1 site in Germany. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2021-09-21.

Sponsored by RWTH Aachen University · Not applicable, Interventional, and Diagnostic

The sponsor has not verified this record recently (last verified Sep 2021), so the status shown — last known as Recruiting — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
70
Allocation
Not applicable
Ages
18 Years to 100 Years
Sex
All
01

Study summary

The aim of the study is to compare capillary blood gas analysis compensated by v-TAC software (aCBGE, aCBGF) to arterial blood gas analysis (ABG) in terms of pH, pCO2 and pO2 and the clinical usefulness of this method compared to the gold standard of ABG.

Read the detailed description

In clinical practice blood gas analysis is an essential tool for monitoring respiratory status. The gold-standard method is arterial blood gas analysis (ABG) of blood from the patient's radial or femoral artery. An alternative to arterial sampling commonly used is arterialized capillary blood gas analysis from the earlobe (CBGE). Though CBGE is less invasive and can be performed by non-medical staff, it is less useful in the acute setting because an adequate vasodilatation is needed which typically lasts for at least 10 minutes and the quality of results tends to be operator dependable. Different trials have evaluated the agreement between ABG and CBGE. Whereas a close agreement between ABG and CBGE has been found for evaluating pH and the partial pressure of carbon dioxide (PCO2), several trials showed considerable variations for the partial pressure of oxygen (PO2) and that CBGE tends to underestimate PO2. Similar findings apply for capillary blood gas analysis from the fingertip (CBGF) which is even less accurate compared to CBGE in estimating PO2. Recently a method has been developed to calculate ABG values mathematically from peripheral venous blood, supplemented with oxygen saturation (SpO2) measurement by pulse oximetry, by use of venous-to-arterial conversion (v-TAC) software (OBI Medical, Denmark). The principle of the method is a mathematical transformation of venous blood gas analysis (VBG) values to arterialised values (aVBG) by simulating the transport of blood back through the tissue (6). This approach leads to a clinically acceptable agreement between ABG and aVBG for pH and PCO2. For PO2 the limits of agreement of aVBG are similar to those of PO2 from CBGE for values below 75 mmHg and with mean bias close to zero. However, it has not been evaluated previously whether v-TAC software can be used to calculate ABG values from CBGE (aCBGE) or CBGF (aCBGF). As CBGE and CBGF values are much closer to ABG values, compared to VBG values, the agreement between aCBGE/aCBGF and ABG in terms of pH, PCO2 and pO2 might be better compared to CBG without mathematical arterialisation by v-TAC.

02

Conditions studied

  • Lung Diseases

Browse trials for

Keywords

  • Arterial blood gas analysis
  • Capillary blood gas analysis
03

In context

Lung Diseases

3,303 studies on the registry are indexed under Lung Diseases; 355 are open to participants now.

This study's planned enrollment of 70 is close to the median of 72 across 2,118 interventional studies indexed under Lung Diseases.

Browse Lung Diseases studies →

Lead sponsor

RWTH Aachen University is the lead sponsor of 228 studies on the registry; 19 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Admission to the intensive / intermediate care or weaning unit at the department of pneumology and intensive care medicine of the university hospital RWTH Aachen
  • Arterial line inserted to monitor the patient's blood pressure or respiratory status
  • Male or female aged ≥ 18 years
  • Written informed consent prior to study participation
  • The subject is willing and able to follow the procedures outlined in the protocol

Exclusion criteria

Exclusion Criteria:

  • Hemodynamic instability
  • Impaired perfusion of peripheral limbs e.g. due to severe heart failure
  • Pregnant and lactating females. Pregnancy will be ruled out in females of childbearing age by pregnancy test.
  • Patient has been committed to an institution by legal or regulatory order
  • The subject is mentally or legally incapacitated
05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
70 participants (estimated)

Study arms

  • Other
    Study Arm

    All patient will be included in this arm

    Diagnostic Test: Study procedure

Interventions

  • Diagnostic testStudy procedure

    * Measurement of the flow rate of supplemental oxygen * Measurement of the peripheral arterial saturation (SpO2) by pulse oximetry * Taking of an ABG sample (ABG1) from the arterial line * Taking of capillary blood gas analysis from the earlobe and from the finger tip * Taking of an a second ABG (ABG2) from the arterial line

06

What researchers measure

Primary outcomes

  1. Comparison of pO2 Levels (in mmHg) in capillary blood samples corrected with VTAC Software to arterial blood samples

    Capillary and arterial pO2 Levels will be measured using a blood gas analyser. Afterwards pO2 levels in the capillary sample will be compensated by VTAC software and compensated pO2 levels will be compared to arterial PO2 levels using the Bland-Altman method.

    Time frame: 10 minutes after the first blood sample is taken

Secondary outcomes

  1. Comparison of pCO2 Levels (in mmHg) in capillary blood samples corrected with VTAC Software to arterial blood samples

    Capillary and arterial pCO2 Levels will be measured using a blood gas analyser. Afterwards pCO2 levels in the capillary sample will be compensated by VTAC software and compensated pCO2 levels will be compared to arterial PCO2 levels using the Bland-Altman method.

    Time frame: 10 minutes after the first blood sample is taken

  2. Comparison of pH in capillary blood samples corrected with VTAC Software to arterial blood samples

    Capillary and arterial pH will be measured using a blood gas analyser. Afterwards pH in the capillary sample will be compensated by VTAC software and compensated pH will be compared to arterial pH levels using the Bland-Altman method.

    Time frame: 10 minutes after the first blood sample is taken

07

Study locations

1 of 1 sites recruiting
  • Clinic for pneumology and internal intensive care
    Aachen, 52074, Germany
    • Michael Dreher, Univ.-Prof. Dr. med. · Contact · mdreher@ukaachen.de
    • Tobias Müller, PD Dr. med. · Principal investigator
    Recruiting
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 21, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04144296
Lead sponsor
RWTH Aachen University
Collaborators
OBI Medical
Responsible party
PD Dr. Tobias Müller (Consultant, RWTH Aachen University) — Principal investigator
First posted
Oct 30, 2019
Start date
Oct 1, 2019
Primary completion
Oct 1, 2021 (estimated)
Completion
Nov 1, 2021 (estimated)
Last update
Sep 21, 2021

Study contacts

Tobias Müller, PD Dr. med.
Contact
tobmueller@ukaachen.de
+492418036470
Ayham Daher, Dr. med.
Contact
adaher@ukaachen.de

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Sep 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion